Cohava Gelber

773 total citations
18 papers, 530 citations indexed

About

Cohava Gelber is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Cohava Gelber has authored 18 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Cohava Gelber's work include Immunotherapy and Immune Responses (5 papers), Immune Cell Function and Interaction (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Cohava Gelber is often cited by papers focused on Immunotherapy and Immune Responses (5 papers), Immune Cell Function and Interaction (3 papers) and Glycosylation and Glycoproteins Research (2 papers). Cohava Gelber collaborates with scholars based in United States, Israel and Argentina. Cohava Gelber's co-authors include Yvonne Reid, Damian Marshall, Helen Parkes, Michael B. Feldman, Lea Eisenbach, Daniel Plaksin, Steven M. Singer, Roland Buelow, Hugh O. McDevitt and Christine Jolicoeur and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and Diabetes.

In The Last Decade

Cohava Gelber

18 papers receiving 515 citations

Peers

Countries citing papers authored by Cohava Gelber

Since Specialization

Citations

This map shows the geographic impact of Cohava Gelber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cohava Gelber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cohava Gelber more than expected).

Fields of papers citing papers by Cohava Gelber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cohava Gelber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cohava Gelber. The network helps show where Cohava Gelber may publish in the future.

Co-authorship network of co-authors of Cohava Gelber

This figure shows the co-authorship network connecting the top 25 collaborators of Cohava Gelber. A scholar is included among the top collaborators of Cohava Gelber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cohava Gelber. Cohava Gelber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity forCEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells 2024 ·Current Cancer Drug Targets ·(unknown), Clinton Enos, Mark Spear, (unknown), (unknown), (unknown), (unknown), Hua‐Bei Guo, (unknown), J. Michael Pierce, Emma E. Furth, (unknown), Yong‐Jun Kwon, Cohava Gelber	3
2	SERPIN-Derived Small Peptide (SP16) as a Potential Therapeutic Agent against HIV-Induced Inflammatory Molecules and Viral Replication in Cells of the Central Nervous System 2023 ·Cells ·(unknown), Myosotys Rodriguez, (unknown), (unknown), Cohava Gelber, Nazira El‐Hage	4
3	Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription 2022 ·Cells ·Catherine DeMarino, Maria Cowen, (unknown), (unknown), Heather Branscome, (unknown), (unknown), Emmanuel Agbottah, Weidong Zhou, Cecilia T. Costiniuk, Mohammad‐Ali Jenabian, Cohava Gelber, Lance A. Liotta, Dianne Langford, Fatah Kashanchi	15
4	Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction 2022 ·Journal of Cardiovascular Pharmacology ·Benjamín Van Tassell, George F. Wohlford, Marco Giuseppe Del Buono, (unknown), Roshanak Markley, Jeremy Turlington, Dinesh Kadariya, Azita H. Talasaz, Jane Ho, Amr Marawan, Georgia Thomas, (unknown), (unknown), Cohava Gelber, Antonio Abbate	3
5	Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC 2022 ·Cancers ·(unknown), Faridoddin Mirshahi, (unknown), Chunqing Guo, (unknown), (unknown), Michael O. Idowu, (unknown), Cohava Gelber, Xiang‐Yang Wang, (unknown), Masoud H. Manjili	4
6	A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers 2021 ·PLoS ONE ·George F. Wohlford, Leo F. Buckley, Dinesh Kadariya, (unknown), Juan Guido Chiabrando, Salvatore Carbone, Virginia Mihalick, Matthew S. Halquist, (unknown), (unknown), Cohava Gelber, Antonio Abbate, Benjamín Van Tassell	10
7	α1‐Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain 2021 ·The FASEB Journal ·Zixuan Wang, Stefano Martellucci, (unknown), (unknown), Cohava Gelber, W. Marie Campana	9
8	Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction 2017 ·JACC Basic to Translational Science ·Stefano Toldo, (unknown), Adolfo G Mauro, Eleonora Mezzaroma, Benjamín W. Van Tassell, Carlo Marchetti, Salvatore Carbone, (unknown), Cohava Gelber, Antonio Abbate	31
9	The Costs of using Unauthenticated, Over-Passaged Cell Lines: How Much more Data do we Need? 2007 ·BioTechniques ·(unknown), Damian Marshall, Yvonne Reid, Helen Parkes, Cohava Gelber	301
10	An 18-year-old male with hematuria, renal insufficiency, and defective synthesis of type IV collagen 2006 ·Kidney International ·Glen S. Markowitz, Cohava Gelber, Vivette D. D’Agati	2
11	A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells 2003 ·Cancer Immunology Immunotherapy ·Pamela Krueger, (unknown), (unknown), (unknown), (unknown), Guita Lalehzadeh, Robert J. Goodson, Jill Winter, Cohava Gelber	7
12	Monoclonal Antibody Identifies a Distinctive Epitope Expressed by Human Multiple Myeloma Cells 2001 ·Journal of Immunotherapy ·Pamela Krueger, (unknown), Jason H. Moore, (unknown), (unknown), Cohava Gelber	6
13	Dendritic cells improve the generation of Epstein-Barr virus–specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma 1998 ·Surgery ·Grayson H. Wheatley, Karen P. McKinnon, (unknown), Sarah Mahon, Cohava Gelber, H. Kim Lyerly	9
14	Dendritic cells improve the generation of Epstein-Barr virus[ndash ]specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma 1998 ·Surgery ·Grayson H. Wheatley, Karen P. McKinnon, (unknown), Sarah Mahon, Cohava Gelber, H. Kim Lyerly	1
15	Isolation of Nonobese Diabetic Mouse T-Cells That Recognize Novel Autoantigens Involved in the Early Events of Diabetes 1994 ·Diabetes ·Cohava Gelber, Lisa R. Paborsky, Steven M. Singer, (unknown), Roland Tisch, Christine Jolicoeur, Roland Buelow, Hugh O. McDevitt, C. Garrison Fathman	41
16	T-cell subset analysis of Lewis lung carcinoma tumor rejection: heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis. 1992 ·PubMed ·Cohava Gelber, Lea Eisenbach, Michael B. Feldman, Robert S. Goodenow	12
17	T-cell subset analysis of 3LL tumor growth 1991 ·International Journal of Cancer ·Cohava Gelber, Lea Eisenbach, Michael B. Feldman, Robert S. Goodenow	1
18	Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. 1988 ·Proceedings of the National Academy of Sciences ·Daniel Plaksin, Cohava Gelber, Michael B. Feldman, Lea Eisenbach	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact